Nanalysis announces closing of acquisition of One Moon Scientific

- July 28th, 2021

Nanalysis Scientific Corp. is pleased to announce that it has successfully closed the previously announced acquisition of One Moon Scientific a New York based magnetic resonance software company that specializes in a suite of software tools to streamline and automate Magnetic Resonance data analysis and management. About Nanalysis Scientific Corp. Nanalysis trades on the TSX Venture Exchange in Canada with ticker …

Nanalysis Scientific Corp. (“the Company”, TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ), is pleased to announce that it has successfully closed the previously announced acquisition of One Moon Scientific (“OMS”), a New York based magnetic resonance software company that specializes in a suite of software tools to streamline and automate Magnetic Resonance (“MR”) data analysis and management.

About Nanalysis Scientific Corp. ( TSXV: NSCI , OTCQX: NSCIF, FRA: 1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol ‘NSCI’ ,Over the Counter (OTC) in the United States under the ticker symbol ‘NSCIF’, and on the Frankfurt Exchange (FRA) under the symbol ‘1N1’.

Nanalysis is an international business focused on capitalizing its proprietary technologies in magnetic resonance (MR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D S.A.S. (RS2D).

Nanalysis Corp. is an industry leader in developing and manufacturing compact MR spectrometers for laboratory and industrial markets. Its advanced 60 and 100 MHz spectrometers require no liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology.

Through its European subsidiary RS2D, the Company’s electronic boards and software are used in conventional NMR and MRI equipment and are being incorporated into next-gen MRI systems as well as miniaturized MRI devices.

To sign up for updates relating to Nanalysis, please click HERE .

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2021/28/c9729.html

News Provided by Canada Newswire via QuoteMedia

Leave a Reply